Low-Dose Sirolimus as Effective as High-Dose for Kaposiform Hemangioendothelioma Treatment, suggests study
Researchers have found in new research that low-dose sirolimus is noninferior to high-dose sirolimus in the treatment of Kaposiform Hemangioendothelioma (KHE), suggesting that lower doses may be a viable treatment option.
It remains unknown whether low-dose sirolimus can replace high-dose sirolimus for the treatment of kaposiform hemangioendothelioma (KHE) without the Kasabach–Merritt phenomenon (KMP). A study was done to evaluate the noninferiority and safety of low-dose versus high-dose sirolimus in Kaposiform Hemangioendothelioma patients.
This randomized, multicenter, open-label, noninferiority trial was conducted from February 2021 to August 2022. Participants received either a low-dose sirolimus regimen (blood trough concentration 5-8 ng/mL) or a high-dose sirolimus regimen (blood trough concentration 10-15 ng/mL). The primary endpoint was the difference in the proportion of patients between groups who achieved an objective response, defined as a ≥20% reduction in Kaposiform Hemangioendothelioma volume at month 12.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.